

Dominic Bettinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6598378/publications.pdf>

Version: 2024-02-01

84
papers

2,896
citations

201385

27
h-index

197535

49
g-index

94
all docs

94
docs citations

94
times ranked

4622
citing authors

#	ARTICLE	IF	CITATIONS
1	Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e179-e187.	2.9	22
2	Comparison of the Covered Self-Expandable Viatorr CX Stent with the Covered Balloon-Expandable BeGraft Peripheral Stent for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation: a Single-Centre Retrospective Study in Patients with Variceal Bleeding. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 542-549.	0.9	7
3	Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 393-393.	0.8	5
4	Hepatic decompensation after transarterial radioembolization (TARE) – a retrospective analysis of risk factors and outcome of patients with HCC. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.2	0
5	Reduction of esophageal stent migration rate with a novel over-the-scope fixation device (with video). <i>Gastrointestinal Endoscopy</i> , 2022, 96, 1-8.	0.5	13
6	Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. <i>Frontiers in Oncology</i> , 2022, 12, 850454.	1.3	7
7	Cytokine adsorption in patients with acute-on-chronic liver failure (CYTOHEP) – a single center, open-label, three-arm, randomized, controlled intervention trial. <i>Trials</i> , 2022, 23, 222.	0.7	6
8	Implantation of transjugular intrahepatic portosystemic shunt (TIPS). <i>Current Opinion in Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.0	4
9	Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study. <i>Hepatology International</i> , 2022, 16, 658-668.	1.9	7
10	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 397-409.	1.8	59
11	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	3.6	114
12	The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 186.	1.7	44
13	FEASIBILITY AND SAFETY OF A NOVEL OVER-THE-SCOPE DEVICE TO FACILITATE ENDOSCOPIC ARGON PLASMA COAGULATION – AN EX-VIVO STUDY. <i>Endoscopy</i> , 2022, 54, .	1.0	0
14	EFFECTIVE REDUCTION OF ESOPHAGEAL STENT MIGRATION RATE WITH A NOVEL OVER-THE-SCOPE FIXATION DEVICE (STENTFIX OTSC). <i>Endoscopy</i> , 2022, 54, .	1.0	0
15	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	2.0	7
16	Relationship between systemic inflammatory response markers and immune treatment related toxicity (IrAEs) in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16204-e16204.	0.8	1
17	Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?. <i>Journal of Internal Medicine</i> , 2021, 289, 121-124.	2.7	51
18	Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. <i>Nature Medicine</i> , 2021, 27, 78-85.	15.2	295

#	ARTICLE	IF	CITATIONS
19	IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 649-660.	1.8	20
20	Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. <i>Liver Cancer</i> , 2021, 10, 360-369.	4.2	25
21	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	1.4	15
22	T cell exhaustion dynamics are linked to clinical outcomes in Hepatocellular Carcinoma. , 2021, 59, .		0
23	Prognostic Value of the CLIFâ€œ AD Score in Patients With Implantation of Transjugular Intrahepatic Portosystemic Shunt. <i>Hepatology Communications</i> , 2021, 5, 650-660.	2.0	10
24	International multicenter experience of transjugular intrahepatic portosystemic shunt implantation in patients with common variable immunodeficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2931-2935.e1.	2.0	4
25	Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic) Tj ETQq1 1 0.784314 rgBT3/Overload 10 Tf 50	1.0	10
26	Blood reelin in the progression of chronic liver disease. <i>Advances in Medical Sciences</i> , 2021, 66, 148-154.	0.9	4
27	Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1369.	1.8	6
28	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. <i>Journal of Hepatology</i> , 2021, 74, 1362-1372.	1.8	74
29	Reply to: â€œlgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?â€œ <i>Journal of Hepatology</i> , 2021, 75, 231-232.	1.8	0
30	Overâ€œtheâ€œscope clip versus transcatheter arterial embolization for refractory peptic ulcer bleedingâ€œA propensity score matched analysis. <i>United European Gastroenterology Journal</i> , 2021, 9, 1048-1056.	1.6	8
31	Reply to: â€œFreiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?â€œ <i>Journal of Hepatology</i> , 2021, 75, 489-490.	1.8	3
32	Reply to: Correspondence on â€œRefining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survivalâ€œ <i>Journal of Hepatology</i> , 2021, 75, 749-750.	1.8	0
33	Reply to: â€œTIPS and liver transplantation should always be discussed togetherâ€œ <i>Journal of Hepatology</i> , 2021, 75, 1002.	1.8	1
34	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	1.3	42
35	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	4.2	33
36	Proton pump inhibitor therapy is associated with reduced survival following first-time transarterial chemoembolization in patients with hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e247-e253.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Plasma Cyclic Guanosine Monophosphate Is a Promising Biomarker of Clinically Significant Portal Hypertension in Patients With Liver Cirrhosis. <i>Frontiers in Medicine</i> , 2021, 8, 803119.	1.2	1
38	Validation of color Doppler ultrasound and computed tomography in the radiologic assessment of non-malignant acute splanchnic vein thrombosis. <i>PLoS ONE</i> , 2021, 16, e0261499.	1.1	7
39	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	3.6	92
40	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 728-735.e4.	2.4	167
41	Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. <i>Liver International</i> , 2020, 40, 215-228.	1.9	27
42	Duodenal-jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome. <i>Obesity Surgery</i> , 2020, 30, 1200-1210.	1.1	10
43	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
44	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. <i>Cancers</i> , 2020, 12, 1862.	1.7	47
45	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
46	Editorial: acute non-cirrhotic and non-malignant portal vein thrombosis--who should be candidates for interventional treatment? Authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 729-730.	1.9	0
47	The Transjugular Intrahepatic Portosystemic Shunt Improves Survival in Patients with Acute Variceal Bleeding: Evidence beyond Randomized Controlled Trials. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1392-1393.	0.2	0
48	A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 329-339.	1.9	31
49	Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16668-e16668.	0.8	5
50	Blood reelin levels in the progression of chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, .	0.2	0
51	A large cervical osteophyte causing dysphagia in an elderly patient. <i>Annals of Gastroenterology</i> , 2020, 33, 687.	0.4	0
52	Seasonal variability of vitamin D status in patients with inflammatory bowel disease – A retrospective cohort study. <i>PLoS ONE</i> , 2019, 14, e0217238.	1.1	11
53	The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. <i>Journal of Hepatology</i> , 2019, 71, 465-472.	1.8	59
54	Endoscopic full-thickness resection for early colorectal cancer. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 1180-1189.e1.	0.5	101

#	ARTICLE	IF	CITATIONS
55	Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. <i>Viruses</i> , 2019, 11, 186.	1.5	34
56	Over-the-scope clips are cost-effective in recurrent peptic ulcer bleeding. <i>United European Gastroenterology Journal</i> , 2019, 7, 1226-1233.	1.6	11
57	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. <i>Liver Cancer</i> , 2019, 8, 281-294.	4.2	31
58	Unusual endoscopic treatment of recurrent cough and pneumonia. <i>Gut</i> , 2019, 68, 1145-1179.	6.1	0
59	Repeated SBRT for in- and out-of-field recurrences in the liver. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 246-253.	1.0	17
60	Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1228-1229.	1.9	0
61	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
62	The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 403-413.	1.0	20
63	Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 801-808.	1.9	19
64	Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). <i>United European Gastroenterology Journal</i> , 2018, 6, 1380-1390.	1.6	24
65	Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>Hepatology Communications</i> , 2018, 2, 1051-1063.	2.0	12
66	Over-the-Scope Clips Are More Effective Than Standard Endoscopic Therapy for Patients With Recurrent Bleeding of Peptic Ulcers. <i>Gastroenterology</i> , 2018, 155, 674-686.e6.	0.6	122
67	Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. <i>BMC Cancer</i> , 2018, 18, 807.	1.1	27
68	Ribavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-4.	0.7	4
69	The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 714-722.	1.9	37
70	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	2.9	66
71	The underdilation of nitinol stents at TIPS implantation: Solution or illusion?. <i>European Journal of Radiology</i> , 2017, 89, 123-128.	1.2	33
72	On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multicentre, prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1146-1155.	1.9	47

#	ARTICLE	IF	CITATIONS
73	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 338-346.	1.8	299
74	Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. <i>Liver Cancer</i> , 2017, 6, 313-324.	4.2	21
75	Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. <i>Radiation Oncology</i> , 2017, 12, 116.	1.2	47
76	Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. <i>BMC Gastroenterology</i> , 2017, 17, 98.	0.8	18
77	The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 15846-15857.	0.8	40
78	Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS). <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1051-1061.	1.9	47
79	Free Hepatic Vein Pressure Is Not Useful to Calculate the Portal Pressure Gradient in Cirrhosis: A Morphologic and Hemodynamic Study. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1130-1137.	0.2	22
80	Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 126-136.	1.9	42
81	Chronic hepatitis E virus infection following allogeneic hematopoietic stem cell transplantation: an important differential diagnosis for graft versus host disease. <i>Annals of Hematology</i> , 2015, 94, 359-360.	0.8	18
82	Editorial: <sc>TIPSS</sc> in patients with cirrhosis and hepatocellular carcinoma – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 231-231.	1.9	0
83	Nonsurgical Therapeutic Options in Portal Vein Thrombosis. <i>Viszeralmedizin</i> , 2014, 30, 5-5.	0.0	7
84	Transfusion-transmitted hepatitis E in Germany, 2013. <i>Eurosurveillance</i> , 2014, 19, .	3.9	81